Hara Oyedeji, DNP, PMHNP-BC
Articles by Hara Oyedeji, DNP, PMHNP-BC
Evaluating Transdermal Asenapine in Schizophrenia
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.
Empowering Patients and Expanding Formulation Options in Schizophrenia Care
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.
Choosing the Right Formulation in Schizophrenia Treatment
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.
Navigating the Schizophrenia Treatment Landscape: Antipsychotic Mechanisms and Evolving Options
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.
Social Determinants of Health and Long-Term Engagement in Schizophrenia Care
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.
Understanding the Multifactorial Causes of Non-Adherence in Schizophrenia
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.
The Clinical and Economic Burden of Poorly Managed Schizophrenia
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.
Outlining the Key Challenges in Schizophrenia Management
ByGustavo Alva, MD, DFAPA,Hara Oyedeji, DNP, PMHNP-BC,Mark Jankelow, MSN, PMHNP-BC,Christoph U. Correll, MD,John M. Kane, MD Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.
